Tags : Multi-Target Strategic Collaboration

Takeda Signs Multi-Target Strategic Collaboration with Prometheus to Develop Targeted

Shots: Prometheus to receive up front, $420M as development, regulatory & commercial milestone with royalties on sales of each program and will be responsible for the identification and validation of three unique drug targets. Takeda to discover, develop & commercialize up to three targeted IBD therapeutics and companion diagnostics The collaboration combines Prometheus’ bioinformatics analysis […]Read More